Droxidopa for Management of Chronic Hypotension in Hemodialysis. [PDF]
Kidney Int RepJayanti A, Elewa M.
europepmc +5 more sources
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension [PDF]
Clinical Neuropharmacology, 2016 Objectives Droxidopa is a prodrug of norepinephrine indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure including Parkinson disease (PD).
Robert A Hauser
exaly +5 more sources
Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension [PDF]
Movement Disorders Clinical Practice, 2019 ABSTRACTBackgroundDroxidopa is approved for adult patients with symptomatic neurogenic orthostatic hypotension (nOH); there is limited information regarding effects on symptoms, outcomes, and quality of life (QOL) beyond two weeks of treatment.ObjectiveExamine the real‐world experience of patients taking droxidopa after six months of treatment ...
Clément François +2 more
exaly +5 more sources
Computational analysis of RNA methyltransferase Rv3366 as a potential drug target for combating drug-resistant Mycobacterium tuberculosis [PDF]
Frontiers in Molecular Biosciences, 2023 Mycobacterium tuberculosis (M.tb) remains a formidable global health threat. The increasing drug resistance among M.tb clinical isolates is exacerbating the current tuberculosis (TB) burden.
Tasmin Nazim +7 more
doaj +2 more sources
Droxidopa for neurogenic orthostatic hypotension [PDF]
Neurology, 2014 To determine whether droxidopa, an oral norepinephrine precursor, improves symptomatic neurogenic orthostatic hypotension (nOH).Patients with symptomatic nOH due to Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa dose optimization (100-600 mg 3 times daily), followed,
Jose-alberto Palma +2 more
exaly +5 more sources
2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension [PDF]
Journal of Clinical and Translational Science, 2018 OBJECTIVES/SPECIFIC AIMS: To describe adverse behavioral symptoms attributed to droxidopa therapy for neurogenic orthostatic hypotension (nOH). METHODS/STUDY POPULATION: BACKGROUND: Droxidopa, a norepinephrine (NE) precursor, improves symptoms of nOH by ...
Katherine McDonell +4 more
doaj +2 more sources
Journal of Pharmaceutical Health Care and Sciences, 2021 Background Patients with chronic heart failure (CHF) are often treated using many diuretics for symptom relief; however, diuretic use may have to continue despite hypotension development in these patients.
Yuki Asai +6 more
doaj +3 more sources
Droxidopa for refractory neurogenic orthostatic hypotension in amyloid light chain amyloidosis
American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2023 Neurogenic orthostatic hypotension (nOH) secondary to amyloidosis is a rare condition associated with significant blood pressure (BP) drops and problematic symptoms for patients.
Hien Ha, Nguyen L Nguyen
openalex +3 more sources
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. [PDF]
Neurol Ther, 2022 Introduction Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa are needed. We have evaluated
Hauser RA +6 more
europepmc +2 more sources
Analysis of L-DOPA and droxidopa binding to human β2-adrenergic receptor
Biophysical Journal, 2021 Over the last two decades, an increasing number of studies has been devoted to a deeper understanding of the molecular process involved in the binding of various agonists and antagonists to active and inactive conformations of β2-adrenergic receptor (β2AR).
Akash Deep Biswas +3 more
semanticscholar +5 more sources